UNSPSC 51322704: Simvastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C25H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AGG2FN16EV, chemically known as 2,2-dimethylbutyric acid, 8-ester with (4r,6r)-6-(2-((1s,2s,6r,8s,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2h-pyran-2-one but generally known as simvastatin, which bears US NIH Compound Identifier 54454.

UNSPSC 51322704 Simvastatin is a Commodity code that encompasses the procurement of specific pharmaceutical products, including statins and other prescription medications, by state and local health agencies, municipalities, and cooperative purchasing alliances. State and local governments buy simvastatin and similar generic prescription drugs through pharmacy benefit programs, emergency medical services supply contracts, and cooperative purchasing vehicles that aggregate demand across multiple jurisdictions. Issuing bodies include city fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances that consolidate procurement for member agencies, school districts, and local facilities. The scope of recent solicitations reflects demand for both individual medications supplied on demand and participation in broader generic pharmaceutical frameworks that establish master pricing and authorized distributor relationships.

Recent activity spans Texas, Florida, and Minnesota-based cooperative purchasing. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for advanced life support medications for Tampa Fire Rescue, a sealed-bid procurement with a $40,000 estimated value and a 5 percent small local business enterprise bid discount, with award made within 120 days to the lowest responsive, responsible bidder. The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for negotiated net pricing outside traditional pharmacy benefit manager arrangements—an exploratory mechanism preceding formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 with a March 26 response deadline for generic multi-source pharmaceutical and OTC product supply across participating state and local facilities in Minnesota and Oregon; the RFP requires vendor pricing competitiveness (75 percent weight), cGMP and Drug Supply Chain Security Act compliance, and relationships with authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson, with a two-year initial term effective July 1, 2026.